Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Ionis Pharma Plummets After GlaxoSmithKline Opts Not to Initiate Phase III Study for Amyloid Cardiomyopathy Drug

Shares of Ionis Pharmaceuticals were down more than 35 percent after its partner GlaxoSmithKline opted to not initiate a Phase III study of its IONIS-TTR drug program for the treatment of patients with TTR amyloidosis.

Read More »

Theranos Now Faces Consumer Class Action Lawsuit

The first lawsuit against embattled blood-testing company Theranos has been filed since the company announced it had invalidated two years of test results.

Read More »

U.S. panel backs approval of Sanofi combination diabetes drug

A U.S. advisory panel recommended approval of a new diabetes drug made by Sanofi SA.

Read More »

Concussions tied to more school problems than other injuries

High school and college students who get concussions may struggle more with academics than their peers who get other types of sports injuries, a small U.S. study suggests.

Read More »

Israeli firms team up for high-speed 3D stem cell printing

Israeli 3D printer firm Nano Dimension has successfully lab-tested a 3D bioprinter for stem cells, paving the way for the potential printing of large tissues and organs, the company said.

Read More »

FDA delays decision on Sarepta’s DMD drug

The U.S. FDA deferred a highly anticipated decision on whether to approve Sarepta Therapeutics Inc.’s muscle-wasting disorder drug.

Read More »

Sanofi to unveil challenge to Medivation’s board

France’s Sanofi SA is preparing to name candidates it will put forward to replace the entire board of U.S. cancer drug company Medivation Inc.

Read More »

Omnicom Health Appoints TBWA\WorldHealth Leadership Team

Omnicom Health Group announced the leadership team for TBWA\WorldHealth, the new agency created by the combination of two healthcare specialist agencies, Corbett and LLNS.

Read More »

Sophiris Bio Slashes Workforce in Half as Firm Explores Strategic Options

Although having successfully completed a Phase III trial assessing its urological disease treatment drug, topsalysin (PRX302), San Diego-based Sophiris has slashed half its workforce in an effort to reduce operating expenses before moving forward with a second Phase III trial.

Read More »

Retired Gilead Exec Returns as His Replacement Exits

Kevin Young will return to Gilead Sciences as the company’s chief operating officer, replacing the man who replaced him when he retired. Bringing Young back into an active role with the company may be a signal the company is moving to solidify its position atop the hepatitis market as other companies develop drugs to challenge its blockbuster therapies, Harvoni and Sovaldi.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2018 Focus: Top 50 Pharma, Company of the Year and more!


Ad Right Bottom